synchro,
I don't follow Amgen closely at all, though I have an acquaintance that works there (see her maybe twice a year, we don't talk shop). Thus I don't know if you're memory is faulty.
Certainly skipping Ph III is quite rare, and it would be a tough call. I would tend to agree with you since ImClone is in good financial shape, and could see C225 through all phases. Still, one could even argue on moral grounds for expediting the process if the drug is that good, not to mention the financial rewards.
I appreciate everyone's forgiveness on my muddle today. I haven't followed ImClone as closely as I did when I owned it this spring; the McCamant plug caught my eye so I posted. I've raised more cash and may look to own it again within a month, though I will build my position slowly given the toppy looking market.
I would guess that even if they don't skip phases for certain protocols/indications, once the drug is approved for one indication, a lot of data will be in for others, and off label usage would be strong.
Again, I know just enough biotech to be dangerous. My two cents only.
Cheers, Tuck |
